Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity-Reference-Cited by-同舟云学术

Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity

Published:2020-08-25 Issue:8 Volume:15 Page:e0238155
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kim Mi Seong,Kim So Hui,Yang Sei Hoon,Kim Min Seuk^ORCID

Funder

Ministry of Education

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Cancer Statistics, 2017;RL Siegel;CA: a cancer journal for clinicians,2017

2. Genetics and biomarkers in personalisation of lung cancer treatment;R Rosell;Lancet,2013

3. Novel drugs against non-small-cell lung cancer;R Pirker;Current opinion in oncology,2014

4. Receptor Tyrosine Kinase-Targeted Cancer Therapy;T Yamaoka;International journal of molecular sciences,2018

5. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors;WR Montor;Molecular cancer,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?;Cancers;2022-11-30

2. Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer;International Journal of Molecular Sciences;2022-02-03

3. Targeting ion channels for the treatment of lung cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-12

4. Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer;Frontiers in Molecular Biosciences;2021-11-05

5. Experimental and mathematical models of intracellular calcium dynamics for evaluating combined anticancer effects of Afatinib and RP4010 in esophageal cancer;2021-08-28